Halozyme Therapeutics’ (HALO) shares jumped 12.7% on Jun 6 after it raised its full-year 2024 financial guidance and updated its five-year financial outlook.This was based on the company’s announcement made earlier this week that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE manufacturing methods.Per Halozyme, the new patent is included in all of HALO's existing and future ENHANZE licenses, meaning that all of it ...